A diluted form of WF10 is marketed by our European subsidiary in parts of Europe, Asia and South America as a topical wound healing agent under several trade names including Oxoferin. By activating macrophages, Oxoferin appears to stimulate the proliferation of fibroblasts - cells that manufacture connective tissue. New connective tissue leads to contraction, closure and faster healing.

Oxoferin has a track record of efficacy in treating chronic wounds. These chronic, hard-to-heal wounds are a serious problem with an increasing incidence. Chronic wounds can be caused by such conditions as burns, pressure sores and poor circulation in the lower extremities. Co-morbid conditions, such as diabetes and atherosclerosis, reduce blood flow to the extremities and also increase the likelihood of developing chronic wounds. In 2002 there were an estimated 5 to 7 million chronic wound cases in the United States and the incidence of these wounds is increasing at approximately 10% per year. In 2002, some 82 thousand people lost a foot or leg to complications from diabetes and the incidence of this complication continues to increase. The advanced wound care market has been estimated to be worth $2.3 billion, and growing at 10 percent per year.

Oxoferin^™ is currently authorized for sale and marketed in India, Indonesia, Pakistan, Thailand and Venezuela. It is marketed by the Company under the name Oxovasin in Germany.

The Company's patents associated with Oxoferin have expired and Nuvo is exploring improved formulations of this product.